HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Other immunosuppressive agents for focal segmental glomerulosclerosis.

Abstract
A prolonged course with corticosteroids represents the first therapeutic approach for nephrotic patients with focal segmental glomerulosclerosis (FSGS). In patients with contraindications to steroids or in those who do not respond to steroids or cyclosporine, cytotoxic agents, mycophenolate mofetil (MMF), plasmapheresis, and low-density lipoprotein (LDL) apheresis have been tried as alternative treatments. A short-term treatment with cytotoxic agents often is ineffective in steroid-resistant patients However, an aggressive and prolonged treatment with cytotoxic agents combined with corticosteroids proved to be effective in more than half of steroid-resistant children. In adults, the response to cytotoxic agents was good in steroid-responsive patients, but was poor in steroid-resistant patients. Better results were observed when cytotoxic therapy was prolonged for several months. The problem with these drugs is that long-term immunosuppression may be complicated by severe side effects including a major risk for cancer. Uncontrolled studies reported that MMF can induce some reduction of proteinuria, but complete remission of proteinuria was rare and no data on long-term follow-up evaluation with this drug are available. Good results have been reported with plasmapheresis, immunoadsorption, and lipopheresis. However, all the reports were uncontrolled, small sized, and with short-term follow-up evaluation. In conclusion, there are several therapeutic options for patients who respond to steroids and have further relapses of nephrotic syndrome, but how to treat steroid-resistant patients is still a matter of debate. Nevertheless, a 6-month trial with cytotoxic agents or MMF can be offered to steroid-resistant patients to identify the few patients who respond to these agents. The preliminary results with plasmapheresis or lipopheresis are promising but further studies are needed to assess the role of these treatments.
AuthorsClaudio Ponticelli, Patrizia Passerini
JournalSeminars in nephrology (Semin Nephrol) Vol. 23 Issue 2 Pg. 242-8 (Mar 2003) ISSN: 0270-9295 [Print] United States
PMID12704585 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright 2003 Elsevier Inc. All rights reserved.
Chemical References
  • Immunosuppressive Agents
  • Proteins
  • Mycophenolic Acid
Topics
  • Disease Progression
  • Dose-Response Relationship, Drug
  • Glomerulosclerosis, Focal Segmental (drug therapy, metabolism)
  • Humans
  • Immunosuppressive Agents (administration & dosage, adverse effects, therapeutic use)
  • Kidney Failure, Chronic (drug therapy, etiology, metabolism)
  • Mycophenolic Acid (analogs & derivatives, therapeutic use)
  • Nephrotic Syndrome (drug therapy, etiology, metabolism)
  • Proteins (drug effects, metabolism)
  • Proteinuria (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: